Evidence that TNF-β (lymphotoxin α) can activate the inflammatory environment in human chondrocytes

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Buhrmann, Constanze ^a   Shayan, Parviz ^b   Aggarwal, Bharat B ^c   Shakibaei, Mehdi ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Investigating Institute of Molecular Biological System Transfer   (Iran)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; COLLAGENASE 3; CURCUMIN; CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LYMPHOTOXIN; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CARTILAGE; CARTILAGE CELL; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENVIRONMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; UPREGULATION; CELL CULTURE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; IMMUNOELECTRON MICROSCOPY; IMMUNOLOGY; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; CHONDROCYTES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LYMPHOTOXIN-ALPHA; MICROSCOPY, IMMUNOELECTRON; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84888209624     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4393     Document Type: Article

References (63)

1. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin: production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984, 259:686-691.
2. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature 1985, 318:665-667. 10.1038/318665a0, 3001529.
3. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin α revisited: general features and implications in rheumatoid arthritis. Arthritis Res Ther 2011, 13:232. 10.1186/ar3376, 3239340, 21861866.
4. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor: production, purification, and characterization. J Biol Chem 1985, 260:2345-2354.
5. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012, 119:651-665. 10.1182/blood-2011-04-325225, 3265196, 22053109.
6. Gramaglia I, Mauri DN, Miner KT, Ware CF, Croft M. Lymphotoxin αβ is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation. J Immunol 1999, 162:1333-1338.
7. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005, 23:787-819. 10.1146/annurev.immunol.23.021704.115719, 15771586.
8. Harris ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990, 322:1277-1289. A published erratum appears in N Engl J Med 1990, 323:994-996, 10.1056/NEJM199005033221805, 2271017.
9. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990, 144:3347-3353.
10. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440. 10.1146/annurev.immunol.14.1.397, 8717520.
11. Joosten LAB, Smeets RL, Koenders MI, van den Bersselaar LAM, Helsen MMA, Oppers-Walgreen B, Lubberts E, Iwakura Y, van de Loo FAJ, van den Berg WB. Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am J Pathol 2004, 165:959-967. 10.1016/S0002-9440(10)63357-3, 1618596, 15331419.
12. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33:305-315. 10.1002/art.1780330302, 2180403.
13. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006, 8:S2.
14. Aggarwal A, Misra R. Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 2003, 23:134-137.
15. Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Ther Adv Chronic Dis 2013, 4:15-21. 10.1177/2040622312466908, 3539265, 23342244.
16. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732. 10.1182/blood-2010-07-273417, 3083294, 21304099.
17. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769. 10.1002/art.20303, 15188351.
18. Criscione LG, St Clair EW. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002, 14:204-211. 10.1097/00002281-200205000-00002, 11981314.
19. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, British Society for Rheumatology Biologics Register Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:583-589. 10.1136/ard.2010.139774, 3048625, 21330639, British Society for Rheumatology Biologics Register.
20. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
21. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α?. Ann Rheum Dis 2004, 63:1344-1346. 10.1136/ard.2003.014878, 1754777, 15033655.
22. O'Rourke KP, O'Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O'Gara F. High levels of lymphotoxin-β (LT-β) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int 2008, 28:979-986. 10.1007/s00296-008-0574-z, 18379788.
23. Robak T, Gladalska A, Stepién H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998, 9:145-154.
24. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino CJ, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck KH, Carano RA, Ferrando R, Diehl L, Chatterjea D, Grogan JL. Targeted depletion of lymphotoxin-α-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15:766-773. 10.1038/nm.1984, 19561618.
25. Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Res Ther 2012, 14:R6. 10.1186/ar3554, 3392792, 22225620.
26. Singh S, Aggarwal BB. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995, 270:24995-25000. A published erratum appears in J Biol Chem 1995, 270:30235, 10.1074/jbc.270.42.24995, 7559628.
27. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995, 49:1551-1556. 10.1016/0006-2952(95)00171-U, 7786295.
28. Funk JL, Frye JB, Oyarzo JN, Kuscuoglu N, Wilson J, McCaffrey G, Stafford G, Chen G, Lantz RC, Jolad SD, Sólyom AM, Kiela PR, Timmermann BN. Efficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis. Arthritis Rheum 2006, 54:3452-3464. 10.1002/art.22180, 17075840.
29. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-κB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445. 10.1016/j.bcp.2007.01.005, 17291458.
30. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003, 21:1457-1465. 10.1038/nbt915, 14647331.
31. Shakibaei M, Shayan P, Busch F, Aldinger C, Buhrmann C, Lueders C, Mobasheri A. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One 2012, 7:e35712. 10.1371/journal.pone.0035712, 3335081, 22539994.
32. Pan WH, Clawson GA. Antisense applications for biological control. J Cell Biochem 2006, 98:14-35. 10.1002/jcb.20790, 16440307.
33. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003, 99:55-77. 10.1016/S0163-7258(03)00053-6, 12804699.
34. Bringman TS, Aggarwal BB. Monoclonal antibodies to human tumor necrosis factors α and β: application for affinity purification, immunoassays, and as structural probes. Hybridoma 1987, 6:489-507. 10.1089/hyb.1987.6.489, 2445655.
35. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23:363-398.
36. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101:1053-1062. 10.1182/blood-2002-05-1320, 12393461.
37. Buhrmann C, Mobasheri A, Matis U, Shakibaei M. Curcumin mediated suppression of nuclear factor-κB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther 2010, 12:R127. 10.1186/ar3065, 2945017, 20594343.
38. Shakibaei M, Sung B, Sethi G, Aggarwal BB. TNF-α-induced mitochondrial alterations in human T cells requires FADD and caspase-8 activation but not RIP and caspase-3 activation. Antioxid Redox Signal 2010, 13:821-831. 10.1089/ars.2009.3036, 2935348, 20136500.
39. Busch F, Mobasheri A, Shayan P, Stahlmann R, Shakibaei M. Sirt-1 is required for the inhibition of apoptosis and inflammatory responses in human tenocytes. J Biol Chem 2012, 287:25770-25781. 10.1074/jbc.M112.355420, 3406664, 22689577.
40. Shakibaei M, John T, De Souza P, Rahmanzadeh R, Merker HJ. Signal transduction by β1 integrin receptors in human chondrocytes in vitro: collaboration with the insulin-like growth factor-I receptor. Biochem J 1999, 342:615-623. 10.1042/0264-6021:3420615, 1220502, 10477272.
41. Shakibaei M, Schulze-Tanzil G, de Souza P, John T, Rahmanzadeh M, Rahmanzadeh R, Merker HJ. Inhibition of mitogen-activated protein kinase kinase induces apoptosis of human chondrocytes. J Biol Chem 2001, 276:13289-13294. 10.1074/jbc.M010859200, 11278768.
42. Shakibaei M, Förster C, Merker HJ, Stahlmann R. Effects of ofloxacin on integrin expression on epiphyseal mouse chondrocytes in vitro. Toxicol In Vitro 1995, 9:107-116. 10.1016/0887-2333(94)00198-4, 20650069.
43. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1β-induced NF-κB-mediated inflammation and apoptosis. Arthritis Res Ther 2009, 11:R165. 10.1186/ar2850, 3003513, 19889203.
44. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000, 18:621-663. 10.1146/annurev.immunol.18.1.621, 10837071.
45. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: its role in health and disease. J Mol Med (Berl) 2004, 82:434-448.
46. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
47. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080.
48. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:518-531. 10.1093/rheumatology/keq316, 21071477.
49. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006, 65:iii61-iii64. 1798381, 17038476.
50. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007, 27:98-114. 10.1016/j.semnephrol.2006.09.013, 17336692.
51. Saxne T, Palladino MA, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988, 31:1041-1045. 10.1002/art.1780310816, 3136775.
52. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989, 2:177-186.
53. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, O'Connor JV. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986, 163:1433-1450. 10.1084/jem.163.6.1433, 2188124, 3486936.
54. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004, 6:203-208. 10.1016/j.ccr.2004.09.003, 15380510.
55. Cheng CY, Kuo CT, Lin CC, Hsieh HL, Yang CM. IL-1β induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol 2010, 160:1595-1610. 10.1111/j.1476-5381.2010.00858.x, 2936833, 20649564.
56. Müller M, Morotti A, Ponzetto C. Activation of NF-κB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 2002, 22:1060-1072. 10.1128/MCB.22.4.1060-1072.2002, 134627, 11809798.
57. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001, 107:7-11. 10.1172/JCI11830, 198552, 11134171.
58. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543. 10.2741/1817, 16146751.
59. Desch CE, Dobrina A, Aggarwal BB, Harlan JM. Tumor necrosis factor-α exhibits greater proinflammatory activity than lymphotoxin in vitro. Blood 1990, 75:2030-2034.
60. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:584-590. 10.1093/rheumatology/kem298, 18234712.
61. Chaturvedi MM, LaPushin R, Aggarwal BB. Tumor necrosis factor and lymphotoxin: qualitative and quantitative differences in the mediation of early and late cellular response. J Biol Chem 1994, 269:14575-14583.
62. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994, 8:504-512.
63. Braun A, Takemura S, Vallejo AN, Goronzy JJ, Weyand CM. Lymphotoxin β-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 2004, 50:2140-2150. 10.1002/art.20356, 15248211.